ARMC5 controls the degradation of most Pol II subunits, and ARMC5 mutation increases neural tube defect risks in mice and humans.

"the dataset is available in proteomexchange (accession number pxd047533) [ ].; the rna-seq dataset is available in the gene expression omnibus (geo; accession number gse169350) [ ].; the chip-seq dataset is available in geo (accession number: gse169582) [ ].; the proteomics dataset is available in proteomexchange (accession number pxd047572) [ ].; availability of data and materials the mouse rna-seq and chip-seq datasets have been deposited to the gene expression omnibus of ncbi (accession numbers gse169350 and gse169582 respectively) [53 70].; mass spectrometry data are available via proteomexchage (accession numbers: pxd047533 and pxd047572) [72]. the microscopy image was deposited in figshare [ ].; the microscopy image was deposited in figshare [ ].; a typical sox2 and nestin staining of wt npcs is presented in fig 2 b the microscopy image was deposited in figshare [ ].; microscopy images have been submitted to figshare [46 49 54]. availability of data and materials the mouse rna-seq and chip-seq datasets have been deposited to the gene expression omnibus of ncbi (accession numbers gse169350"

"filtered high-quality snvs were annotated using the non-synonymous snv functional predictions database [ ] with an in-house python script for all current functional prediction information publicly available."

"Declarations Ethics approval and consent to participateAll the animal studies (Protocol IP20018JWs were approved by the Animal Protection Committee (Comité institutionnel d'intégration de la protection des animaux) of the CRCHUM. Human subjects were recruited with written consent to the research studies. The protocol (HSC-MS-00–001) for this human study was approved by the University of Texas Health Science Center at Houston Committee for the Protection of Human Subjects. The protocol complies with the Helsinki Declaration. Competing interestsThe authors declare that they have no competing interests. Competing interests The authors declare that they have no competing interests."

"Funding This work was supported by the Jean-Louis Levesque Foundation to JW. It was also funded in part by grants from the Natural Sciences and Engineering Research Council of Canada (RGPIN-2017–04790), the Arthritis Society of Canada, the Canadian Institutes of Health Research (PJT-180284), and the Canadian Rare Disease Models and Mechanisms Network to JW, by a grant from NIH/NICHD (R01HD073434) to KSA, and by a development grant from the Ministère de l’Économie, de l’Innovation et de l’Énergie, Québec to BC."